Home/Pipeline
Program
PreclinicalPhase 1Phase 2Phase 3FiledApproved
Next milestoneCLV-131emzaratinibNSCLC adjuvantOncology · Small molecule
Phase 3 readout 2027
CLV-211corvatinibCrohn's diseaseImmunology · Small molecule
Phase 3 enrollment complete
CLV-310Parkinson's diseaseNeuroscience · Small molecule
Phase 3 readout 2027
CLV-412lorvatideObesityCardiometabolic · Peptide
Phase 3 readout H2 2027
Pipeline as of September 30, 2026. Programs and data are fictional.